Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Lieberman, T. Stroup, J. McEvoy, J. McEvoy, M. Swartz, R. Rosenheck, D. Perkins, R. Keefe, S. Davis, C. Davis, B. Lebowitz, J. Severe, J. Hsiao (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, 353 12
R. Rosenheck, D. Leslie, J. Sindelar, E. Miller, Haiqun Lin, T. Stroup, J. McEvoy, S. Davis, R. Keefe, M. Swartz, D. Perkins, J. Hsiao, J. Lieberman (2006)
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.The American journal of psychiatry, 163 12
S. Woods, H. Morgenstern, J. Saksa, B. Walsh, M. Sullivan, R. Money, K. Hawkins, R. Gueorguieva, W. Glazer (2010)
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.The Journal of clinical psychiatry, 71 4
R. Rosenheck (2007)
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychoticsBritish Journal of Psychiatry, 191
DD Miller, SN Caroff, SM Davis, RA Rosenheck, JP McEvoy, BL Saltz, MS Swartz, RSE Keefe, TS Stroup, JA Lieberman (2008)
Extrapyramidal side effects of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaBritish Journal of Psychiatry, 193
JA Lieberman, S Stroup, J McEvoy, M Swartz, R Rosenheck, D Perkins, RSE Keefe, S Davis, CE Davis, J Hsiao, J Severe, B Lebowitz (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trialNew England Journal of Medicine, 353
Del Miller, Stanley Caroff, S. Davis, Robert Rosenheck, J. Mcevoy, B. Saltz, S. Riggio, M. Chakos, M. Swartz, Richard Keefe, T. Stroup, Jeffrey Lieberman (2008)
Extrapyramidal side-effects of antipsychotics in a randomised trialBritish Journal of Psychiatry, 193
RA Rosenheck (2007)
Considerations for evaluating the cost-effectiveness of reducing tardive dyskinesia with second generation antipsychoticsBritish Journal of Psychiatry, 191
A number of innovative delivery systems for acute antipsychotic pharmacotherapy have been developed over the years which include oral suspensions, rapidly dissolving wafers and acute intramuscular preparations. Currently, the availability of first generation antipsychotic (FGA) formulations is limited to two high potency agents: haloperidol and fluphenazine. At Yale New-Haven Psychiatric Hospital, the hospital pharmacy was able to create perphenazine suspension, a mid-potency FGA, with a record of effectiveness and tolerability that was no worse than that of second generation antipsychotics (SGAs) in the CATIE trial. In this study we compare perphenazine suspension to other first and SGAs in the risk of extrapyramidal reactions and whether or not patients were continued on the same antipsychotic they were started with at the time of discharge. Medical records of patients who received acute pharmacotherapy in a unique form while hospitalized at Yale New Haven Psychiatric Hospital from July 2009 to December 2009 were examined. All data were collected thru a chart review using a form that was created to systematically document experiences. A total of 229 patients were included in the study. There were no significant differences between treatment groups on gender, age, race or diagnosis. In the entire samples 1.75% had pseudo-parkonisnism, 1.31% had acute dystonia, 0.04% had tardive dyskinesia, 1.31% akithesia, and 4.8% any neurological side effects. There were no significant differences between agents in the likelihood of any of these side effects or of having any side effect. Higher use of anticholinergics was found in patients treated with FGAs. We also found that 77% were discharged on the same antipsychotic agent they received when they were initially hospitalized. A wide range of acute oral pharmacoptherapy in non-tablet formulations of first and SGAs should be available in psychiatric hospital formularies. FGAs seems to be as well tolerated as SGAs.
Psychiatric Quarterly – Springer Journals
Published: Jan 24, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.